The vaccine targets and eliminates the alpha-synuclein protein, whose clumping is a sign of PD.
PD01 vaccine has shown to stimulate the immune system to release antibodies that bind to the protein alpha-synuclein, clearing it from the brain and slowing disease progression.
MJFF CEO Todd Sherer said PD01 represents the first vaccine approach to Parkinson´s disease that has been studied in the clinic.
MJFF intends to expand its research presence in Austria with the award.